Photocure ASA ((PHCUF)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The clinical study titled ‘Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy’ aims to enhance bladder cancer detection through the integration of artificial intelligence with blue light cystoscopy (BLC). The study’s primary objective is to collect images, videos, and pathology results from BLC procedures to develop an AI decision support tool, potentially improving diagnostic accuracy. This research holds significant promise in advancing bladder cancer diagnostics.
The intervention under investigation is the blue light cystoscopy, a diagnostic procedure that uses a drug to induce fluorescence in cancerous cells under blue light, aiding in the visualization of bladder lesions. The study seeks to leverage AI to further refine this process.
Designed as an observational cohort study with a prospective time perspective, the research involves adult patients scheduled for BLC as part of their clinical practice. There is no allocation or masking involved, as the primary purpose is data collection for AI development.
Key dates for the study include its start date on August 20, 2025, which marks the beginning of data collection. The primary completion and estimated completion dates are yet to be announced. The last update was also on August 20, 2025, indicating the study’s current status as not yet recruiting.
The potential market implications of this study are significant for Photocure ASA (PHCUF), as successful development of the AI tool could enhance the company’s competitive edge in the bladder cancer diagnostic market. This could positively influence stock performance and investor sentiment, especially given the increasing focus on AI in healthcare.
The study is ongoing, with further details available on the ClinicalTrials portal.